Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis

Clinical Transplantation

Volumn 30, Issue 3, 2016, Pages 270-278

  Beam, E ^a   Lesnick, T ^a   Kremers, W ^a   Kennedy, C C ^a   Razonable, R R ^a  

^a Mayo Clinic College of Medicine   (United States)

Author keywords

Cytomegalovirus; Extended prophylaxis; Lung transplant

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CYCLOSPORIN; GANCICLOVIR; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ARTICLE; CYTOMEGALOVIRUS INFECTION; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; INFECTION PREVENTION; LEUKOPENIA; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANTIBIOTIC PROPHYLAXIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DRUG EFFECTS; GRAFT REJECTION; GRAFT SURVIVAL; LUNG DISEASES; MIDDLE AGED; MINNESOTA; POSTOPERATIVE COMPLICATION; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE; VIROLOGY;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; MINNESOTA; POSTOPERATIVE COMPLICATIONS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84959313086     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12686     Document Type: Article

References (18)

1. Thabut G, Christie JD, Kremers WK, Fournier M, Halpern SD. Survival differences following lung transplantation among US transplant centers. JAMA 2010: 304: 53.
2. Kreisel D, Krupnick AS, Puri V, et al. Short- and long-term outcomes of 1000 adult lung transplant recipients at a single center. J Thorac Cardiovasc Surg 2011: 141: 215.
3. Valapour M, Skeans MA, Heubner BM, et al. OPTN/SRTR 2012 Annual Data Report: lung. Am J Transplant 2014: 14(Suppl 1): 139.
4. Witt CA, Meyers BF, Hachem RR. Pulmonary infections following lung transplantation. Thorac Surg Clin 2012: 22: 403.
5. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010: 50: 1101.
6. Parada MT, Alba A, Sepulveda C. Early and late infections in lung transplantation patients. Transplant Proc 2010: 42: 333.
7. Bridevaux PO, Aubert JD, Soccal PM, et al. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax 2014: 69: 32.
8. Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013: 96: 333.
9. Razonable R. Direct and indirect effects of cytomegalovirus: can we prevent them? Enferm Infecc Microbiol Clin 2010: 28: 1.
10. Wiita AP, Roubinian N, Khan Y, et al. Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 2012: 14: 248.
11. Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009: 28: 670.
12. Hodson EM, Ladhani M, Webster AC, Strippoli GF, Craig JC. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients. Cochrane Database Syst Rev 2013: 2: CD003774.
13. Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010: 152: 761.
14. Le Page AK, Jager MM, Kotton CN, Simoons-Smit A, Rawlinson WD. International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines. Transplantation 2013: 95: 1455.
15. Zuk DM, Humar A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation 2010: 90: 672.
16. Schoeppler KE, Lyu DM, Grazia TJ, Crossno JT Jr, Vandervest KM, Zamora MR. Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis? Am J Transplant 2013: 13: 376.
17. Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004: 4: 1635.
18. Mitsani D, Nguyen MH, Kwak EJ, et al. Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis. J Heart Lung Transplant 2010: 29: 1014.